Le linee guida dell’OMS per la gestione delle infezioni sessualmente […]
Search Results for: Dalla presbifagia alla sarcopenia, il trattamento in medicina generale
Here's what we've found for you
Chi guida oggi la sanità pubblica? L’identikit dei direttori generali in Italia
Nel cuore delle aziende sanitarie pubbliche italiane si trova una figura chiave, spesso poco conosciuta fuori dai circuiti istituzionali, ma determinante per la salute del sistema: il direttore generale. È…
Farmaci e caldo: gli effetti imprevisti, le reazioni e come conservarli se si viaggia. Ecco l'elenco
Caldo, afa? Anche i farmaci “soffrono”. Ma cosa accade davvero ai medicinali quando le temperature schizzano così in alto come in questi giorni?Disattenzioni come lasciare una medicina in macchina o…
Tra bisturi e algoritmi, nascono i primi medici-ingegneri d’Europa
Un traguardo storico per la formazione universitaria europea: si è concluso oggi il primo ciclo di MedTec School, l’innovativo corso di Laurea internazionale in Medicina e Chirurgia e Ingegneria Biomedica,…
Linea guida sulla gestione della malattia venosa cronica
La Society for Cardiovascular Angiography and Interventions (SCAI) ha pubblicato una linea guida sulla […]
Tailoring Obesity Management to Support Physical Function in Older Adults
To the Editor We appreciate the timely publication of the Viewpoint by Golovaty and Hagan on comprehensive lifestyle intervention (CLI) requirements for novel medications in treating obesity. Their commentary is particularly relevant given the rise in obesity-related complications among older adults and the recent evidence of the treatment efficacy of novel incretin-mimetics. Our intent is to offer additional nuance and complexity to this discussion by examining the intersection of obesity, aging, and sarcopenia in clinical care.
Study protocol to assess clinical outcomes of breast cancer and its relationship with access to healthcare in Brazil–BREAST trial (BRaziLian outcomE for metAStatic breasT cancer): a prospective observational study in HER2-negative/hormone receptor-positive metastatic disease
Introduction
Breast cancer survival rates in low-income and middle-income countries significantly differ from those in high-income countries, indicating limited access to first-line systemic therapy for advanced and metastatic tumours. Recent studies have demonstrated the benefits of combining cyclin-dependent kinase 4 and 6 inhibitors (CDK 4/6) with endocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. However, in Brazil, the population faces limited access to these drugs, particularly in the public healthcare system.
Methods and analysis
This prospective observational study will enrol 300 female patients from 20 cancer centres across Brazil, divided into two groups based on healthcare coverage: those treated in the public healthcare system (group 1) and those treated in the private healthcare system (group 2). The use or non-use of CDK 4/6 inhibitors is not dictated by the study protocol but rather reflects real-world treatment decisions made by attending physicians. Patients will be followed for 24 months, stratified according to CDK 4/6 inhibitor usage. The project aims to assess health inequities by evaluating the prognosis of patients treated in the public versus private healthcare systems. Outcomes include progression-free survival (PFS), overall survival (OS), quality of life and cost-effectiveness. Kaplan-Meier curves will be used to analyse PFS and OS, while the Cox proportional hazards frailty model will be employed to compare outcomes between healthcare systems, adjusting for prognostic variables.
Ethics and dissemination
The study protocol was approved by the Ethics Committee of the HCor Research Institute (Hospital do Coracão/Associacão Beneficente Síria), which served as the central ethics board for the trial (study number: CAAE 42538621.5.1001.0060; approval letter number: 4.571.507; date: 3 March 2021). All participating centres also obtained approval from their respective local ethics committees prior to patient enrolment: Ethics Committee of Hospital de Câncer de Barretos—Fundacão Pio XII; Ethics Committee of Universidade Estadual de Campinas—UNICAMP; Ethics Committee of Faculdade de Minas Muriaé—FAMINAS; Ethics Committee of Hospital Santa Paula—SP; Ethics Committee of Hospital Alemão Oswaldo Cruz—SP; Ethics Committee of Hospital Regional do Câncer de Presidente Prudente—HRCPP; Ethics Committee of Instituto Brasileiro de Controle do Câncer—IBCC/Oncologia Clínica—SP; Ethics Committee of Instituto de Medicina Integral Prof. Fernando Figueira—IMIP/PE; Ethics Committee of Hospital São Rafael; Ethics Committee of Universidade Federal de São Paulo—UNIFESP; Ethics Committee of Hospital Geral de Fortaleza—HGF; Ethics Committee of Casa de Saúde Santa Marcelina; Ethics Committee of Centro Universitário FMABC; Ethics Committee of Liga Norte Riograndense Contra o Câncer; Ethics Committee of Hospital Mãe de Deus/Associacão Educadora São Carlos—AESC; and Ethics Committee of Instituto do Câncer Brasil—ICB. All patients will provide written informed consent. Study findings will be disseminated through scientific publications and presented to a broad range of stakeholders, including patients, physicians, the general public and policymakers.
Trial registration number
ClinicalTrials.gov identifier: NCT05559528—BRaziLian outcomE for metAStatic breasT cancer (BREAST).
Parkinson, trattamento innovativo con follow up in televisita
Per la fase avanzata. Al San Carlo di Potenza
Micro sensori che trasmettono dati da dentro il corpo: ecco come le protesi smart rivoluzionano la medicina
La raccolta dei dati sanitari non è più solo ricavata da un esame o dal risultato di un’analisi. Ora arriva direttamente dall’interno del nostro corpo e promette una rivoluzione per…
Una scoperta sul sistema immunitario rivela una potenziale soluzione all’Alzheimer
Gli scienziati della Facoltà di Medicina dell’Università della Virginia hanno studiato la […]
Presentato il nuovo centro dell'Iit in Valle d'Aosta
Focus su medicina di precisione con genomica e IA
Speranze da trattamento meno invasivo per raro tumore della colonna vertebrale
Studio dell’Istituto nazionale tumori su terapia non chirurgica
Tumore colonna vertebrale, speranze da trattamento meno invasivo
Studio dell’Istituto nazionale tumori su terapia non chirurgica
Daniele Piacentini nuovo direttore generale Fondazione Gemelli
Dal primo luglio succede a Marco Elefanti
Tumori, a Milano la prima termoablazione con risonanza magnetica
Intervento su fegato. “Innovazione trattamento neoplasie”
Tumori, a Milano la prima termoablazione con risonanza magnetica
Intervento su fegato. “Innovazione trattamento neoplasie”